Tato stránka byla automaticky přeložena a přesnost překladu není zaručena. Podívejte se prosím na anglická verze pro zdrojový text.

Hodnocení SPN-812 (Viloxazinová kapsle s prodlouženým uvolňováním) u dětí předškolního věku s ADHD

2. října 2026 aktualizováno: Supernus Pharmaceuticals, Inc.

Fáze 4, randomizovaná, dvojitě zaslepená, multicentrická, placebem kontrolovaná, paralelně skupinová studie účinnosti a bezpečnosti SPN-812 u dětí předškolního věku (4 až 5 let) s poruchou pozornosti/hyperaktivitou (ADHD )

This study will evaluate the efficacy and safety of SPN-812 (viloxazine extended release) in children 4 to 5 years of age with ADHD.

Přehled studie

Postavení

Nábor

Detailní popis

This is a randomized, double-blind, placebo-controlled, multicenter, 2-arm (1:1), parallel-group, efficacy and safety/tolerability fixed-dose study of SPN-812 in preschool-age children (4 to 5 years old) with ADHD. Participants will be screened for eligibility for up to 4 weeks. Eligible participants will be treated with study medication for 6 weeks. The total duration of the study is up to 10 weeks.

Typ studie

Intervenční

Zápis (Odhadovaný)

286

Fáze

  • Fáze 4

Kontakty a umístění

Tato část poskytuje kontaktní údaje pro ty, kteří studii provádějí, a informace o tom, kde se tato studie provádí.

Studijní kontakt

Studijní místa

    • Alabama
    • Arkansas
      • Fayetteville, Arkansas, Spojené státy, 72703
        • Staženo
        • Preferred Research Partners-NWA, LLC
      • Little Rock, Arkansas, Spojené státy, 72211
    • California
      • Anaheim, California, Spojené státy, 92805
        • Nábor
        • Advanced Research Center (ARC), Inc.
        • Kontakt:
      • Encino, California, Spojené státy, 91316
        • Staženo
        • Wake Research-Pharmacology Research Institute (WR-PRI), LLC [Encino]
      • Garden Grove, California, Spojené státy, 92844
        • Ukončeno
        • National Institute of Clinical Research (PICR)
      • Imperial, California, Spojené státy, 92251
      • Long Beach, California, Spojené státy, 90807
      • Newport Beach, California, Spojené státy, 92660
        • Staženo
        • Wake Research-Pharmacology Research Institute (WR-PRI), LLC [Newport Beach]
    • Colorado
      • Centennial, Colorado, Spojené státy, 80112
        • Nábor
        • IMMUNOe Research Centers
        • Kontakt:
        • Kontakt:
          • Telefonní číslo: 303-773-9000
    • Florida
      • Clermont, Florida, Spojené státy, 34711
        • Staženo
        • Vertex Clinical Research, LLC
      • Coral Gables, Florida, Spojené státy, 33134
        • Nábor
        • Luna Research Center
        • Kontakt:
          • Telefonní číslo: 305-613-7761
      • Gainesville, Florida, Spojené státy, 32607
        • Ukončeno
        • Sarkis Clinical Trials
      • Jacksonville, Florida, Spojené státy, 32256
        • Nábor
        • Clinical Neuroscience Solutions, Inc.
        • Kontakt:
          • Telefonní číslo: 904-281-5757
      • Lakeland, Florida, Spojené státy, 33803
        • Ukončeno
        • Accel Research Sites - Lakeland CRU
      • Miami, Florida, Spojené státy, 33155
      • Orange City, Florida, Spojené státy, 32763
        • Nábor
        • Medical Research Group of Central Florida
        • Kontakt:
          • Telefonní číslo: 386-775-7627
      • Orlando, Florida, Spojené státy, 32801
      • Orlando, Florida, Spojené státy, 32803
        • Nábor
        • APG Research LLC
        • Kontakt:
        • Kontakt:
          • Telefonní číslo: 165 407-423-7149
      • Tamarac, Florida, Spojené státy, 33321
        • Nábor
        • D&H Tamarac Research Center
        • Kontakt:
      • Virginia Gardens, Florida, Spojené státy, 33166
      • Winter Park, Florida, Spojené státy, 32789
    • Georgia
      • Atlanta, Georgia, Spojené státy, 30328
        • Nábor
        • Clinical Integrative Research Center of Atlanta
        • Kontakt:
          • Telefonní číslo: 678-705-7341
      • Atlanta, Georgia, Spojené státy, 30318
      • Decatur, Georgia, Spojené státy, 30030
        • Nábor
        • CenExcel iResearch, LLC
        • Kontakt:
          • Telefonní číslo: 404-537-1281
      • Savannah, Georgia, Spojené státy, 31405
        • Nábor
        • CenExel iResearch, LLC.
        • Kontakt:
          • Telefonní číslo: 912-744-0800
    • Indiana
      • Evansville, Indiana, Spojené státy, 47715
        • Ukončeno
        • Qualmedica Research, LLC.
    • Kentucky
      • Bardstown, Kentucky, Spojené státy, 40004
        • Nábor
        • Kentucky Pediatric/Adult Research
        • Kontakt:
      • Owensboro, Kentucky, Spojené státy, 42301
        • Ukončeno
        • Qualmedica Research, LLC.
    • Louisiana
      • New Orleans, Louisiana, Spojené státy, 70115
        • Ukončeno
        • DelRicht Research (Touro Medical Center)
      • Prairieville, Louisiana, Spojené státy, 70769
        • Nábor
        • DelRicht Research
        • Kontakt:
    • Maryland
      • Baltimore, Maryland, Spojené státy, 21205
        • Nábor
        • Kennedy Krieger Institute
        • Kontakt:
          • Telefonní číslo: 443-923-3850
    • Massachusetts
      • Boston, Massachusetts, Spojené státy, 02445
    • Michigan
      • Bloomfield Hills, Michigan, Spojené státy, 48302
        • Nábor
        • Neurobehavioral Medicine Group
        • Kontakt:
    • Mississippi
      • Flowood, Mississippi, Spojené státy, 39232
        • Nábor
        • Precise Research Centers
        • Kontakt:
          • Telefonní číslo: 601-420-5812
    • Nevada
      • Las Vegas, Nevada, Spojené státy, 89128
        • Nábor
        • Clinical Research of Southern Nevada, LLC.
        • Kontakt:
    • New Jersey
      • Berlin, New Jersey, Spojené státy, 08009
        • Staženo
        • Hassman Research Institute
      • Irvington, New Jersey, Spojené státy, 07111
      • Neptune City, New Jersey, Spojené státy, 07753
        • Nábor
        • Jersey Shore University Medical Center
        • Kontakt:
    • New York
      • New York, New York, Spojené státy, 10028
        • Staženo
        • Icahn School of Medicine at Mount Sinai
    • North Carolina
      • Durham, North Carolina, Spojené státy, 27705
        • Nábor
        • Duke University
        • Kontakt:
          • Telefonní číslo: 919-681-1100
    • Ohio
      • Cincinnati, Ohio, Spojené státy, 45229
        • Nábor
        • Cincinnati Children's Hospital and Medical Center
        • Kontakt:
      • West Chester, Ohio, Spojené státy, 45069
        • Staženo
        • CincyScience
    • Oregon
      • Gresham, Oregon, Spojené státy, 97030
        • Nábor
        • Cyn3rgy Research
        • Kontakt:
    • Pennsylvania
      • Hershey, Pennsylvania, Spojené státy, 17033
        • Nábor
        • Penn State Health Medical Group - Psychiatry and Behavioral Health
        • Kontakt:
        • Kontakt:
          • Telefonní číslo: 717-531-5656
    • South Carolina
      • North Charleston, South Carolina, Spojené státy, 29405
      • Summerville, South Carolina, Spojené státy, 29486
    • Tennessee
      • Memphis, Tennessee, Spojené státy, 38119
        • Nábor
        • Clinical Neuroscience Solutions, Inc.
        • Kontakt:
          • Telefonní číslo: 901-843-1045
    • Texas
      • Bellaire, Texas, Spojené státy, 77401
        • Staženo
        • Houston Clinical Trials, LLC.
      • Dallas, Texas, Spojené státy, 75230
        • Ukončeno
        • Javara
      • Plano, Texas, Spojené státy, 75093
        • Nábor
        • AIM Trials, LLC
        • Kontakt:
        • Kontakt:
          • Telefonní číslo: 214-856-2778
      • The Woodlands, Texas, Spojené státy, 77381
    • Virginia
      • Petersburg, Virginia, Spojené státy, 23805
      • Richmond, Virginia, Spojené státy, 23220
        • Nábor
        • Virginia Commonwealth University, Virginia Treatment Center for Children
        • Kontakt:
          • Telefonní číslo: 804-628-8736

Kritéria účasti

Výzkumníci hledají lidi, kteří odpovídají určitému popisu, kterému se říká kritéria způsobilosti. Některé příklady těchto kritérií jsou celkový zdravotní stav osoby nebo předchozí léčba.

Kritéria způsobilosti

Věk způsobilý ke studiu

4 roky až 5 let (Dítě)

Přijímá zdravé dobrovolníky

Ne

Pohlaví způsobilá ke studiu

Všechno

Popis

Inclusion Criteria:

  1. Is male or female 4 years 0 months of age to less than or equal to 5 years 9 months of age at Visit 1 (Screening) and considered medically healthy.
  2. Subject's parent(s) or legal guardian(s)/representative(s) is (are) willing and able to provide written informed consent before completing any study related procedures.
  3. Has a primary diagnosis of ADHD according to DSM-IV-TR criteria and confirmed with the Kiddie Schedule for Affective Disorders and Schizophrenia - Present and Lifetime Version (K-SADS-PL).
  4. Has an ADHD-RS-IV-P Total Score of ≥ 28 (males) or ≥ 24 (females) at Visit 1 (Screening) and at Visit 2 (Baseline).
  5. Has a CGI-S score of ≥ 4 (moderate or worse) at Visit 1 (Screening) and at Visit 2 (Baseline).
  6. Has undergone an adequate course of non-pharmacologic treatment or is having symptoms severe enough to warrant pharmacologic treatment without prior non-pharmacologic treatment.
  7. Is participating in a structured group activity (e.g., preschool, kindergarten, sports, Sunday school, summer camp or childcare program) at least 2 days a week during study so as to assess symptoms and impairment in a setting outside the home.
  8. Has not initiated any behavioral intervention/therapy within 30 days of Visit 1 (Screening) and does not plan to initiate any new or discontinue any ongoing behavioral intervention/therapy during the study (e.g., subject is eligible if behavioral intervention/therapy is initiated 30 or more days prior to Visit 1 [Screening] and continues with a similar duration/frequency throughout their study).
  9. Subjects who are on ADHD medication at Visit 1 (Screening), but whose ADHD symptoms are not well controlled on current ADHD medication (e.g., meets Inclusion Criterion #4), meet all other inclusion/exclusion criteria, and discontinues ADHD medication at least 7 days prior to the day of Visit 2 (Baseline) are eligible to participate.
  10. Has no current condition in the opinion of the Investigator that could confound efficacy assessments, safety assessments or increase participant risk.
  11. Has lived with the same parent(s) or legal guardian(s) or has lived under a shared living arrangement (e.g., joint legal custody) for greater than or equal to 6 months prior to Visit 1 (Screening).
  12. Has a body weight ≥5th percentile for age and sex at Visit 1 (Screening) and Visit 2 (Baseline).

Exclusion Criteria:

  1. Has a diagnosis at Screening (per K-SADS-PL) of another psychiatric disorder that is considered to be the primary diagnosis rather than ADHD or has a comorbid psychiatric disorder secondary to ADHD that, in the opinion of the investigator (after consulting medical monitor), will likely interfere with study treatment adherence and/or impact study results.
  2. Has a current diagnosis of a major neurological disorder. The eligibility of those who have seizures, a history of seizure-like events (e.g., syncope, myoclonus, severe muscle spasms), a family history of seizure disorder (immediate family, i.e., sibling, parent), and/or febrile seizures will be assessed on a case-by-case basis after consulting the medical monitor.
  3. History of Bipolar Disorder diagnosed in a first degree relative.
  4. Has global development delay or intellectual disability by medical history.
  5. Has a current diagnosis of a significant (per Investigator's evaluation and/or judgement) systemic disease.
  6. Has body mass index > 95th percentile for the subject's age and sex at Visit 1 (Screening) or Visit 2 (Baseline).
  7. Has a mean resting systolic and diastolic blood pressure* that are both >95th percentile for age sex, and height and has a mean resting pulse rate* that is >95th percentile for age and sex (males: >117 bpm; females: >122 bpm) at Visit 1 (Screening) or Visit 2 (Baseline). * Note: The mean of three measurements while seated.
  8. Has a clinically significant electrocardiogram finding(s) at Visit 1 (Screening).
  9. Is currently taking SPN-812 for ADHD, has previously taken SPN-812 for ADHD, but discontinued due to a lack of efficacy or adverse reactions, or has history of allergic reaction, hypersensitivity or intolerance to viloxazine.
  10. Has an allergy to or cannot swallow pudding and applesauce and cannot swallow intact capsule whole.
  11. Has any food allergy, intolerance, restriction or special diet that, in the opinion of the Investigator, could contraindicate the subject's participation in the study.
  12. Has received any investigational drug within the longer of 30 days or 5 half-lives prior to Visit 2 (e.g., first dose of study medication).
  13. Has a positive urine drug test at Visit 1 (Screening). A positive test for amphetamines is allowed for subjects receiving a stimulant ADHD medication at Screening. The subject will be required to discontinue the stimulant for the duration of the study, beginning at least 7 days prior to Visit 2 (Baseline).
  14. Is using of prohibited concomitant medications including known CYP1A2 substrates (e.g., theophylline, melatonin) during the Screening Period or (anticipated) for the duration of the study.
  15. Any reason that, in the opinion of the Investigator, would prevent the subject from participating in the study.
  16. Has suicidal ideation ("Yes" indicated on C-SSRS question 4 or 5) or suicidal behavior ("Yes" indicated on C-SSRS for any suicidal behavior) within 6 months prior to or the day of Visit 1 (Screening) or has attempted suicide ("Yes" indicated on C-SSRS for lifetime).

Studijní plán

Tato část poskytuje podrobnosti o studijním plánu, včetně toho, jak je studie navržena a co studie měří.

Jak je studie koncipována?

Detaily designu

  • Primární účel: Léčba
  • Přidělení: Randomizované
  • Intervenční model: Paralelní přiřazení
  • Maskování: Čtyřnásobek

Zbraně a zásahy

Skupina účastníků / Arm
Intervence / Léčba
Komparátor placeba: Placebo

Placebo, qd

Placebo will be administered once daily

Experimentální: SPN-812

SPN-812, qd

100mg SPN-812 will be administered once daily and compared to Placebo

Ostatní jména:
  • SPN-812

Co je měření studie?

Primární výstupní opatření

Měření výsledku
Popis opatření
Časové okno
Change from Baseline in the Attention-Deficit/Hyperactivity Disorder Rating Scale, 4th Edition, Preschool Version (ADHD-RS-IV-P) Total Score at End of Study (Week 6)
Časové okno: Baseline and Week 6

The Attention-Deficit/Hyperactivity Disorder Rating Scale, 4th Edition, Preschool Version (ADHD-RS-IV-P) consists of 18 items that correspond directly to the DSM-IV-TR criteria for ADHD. The scale is subdivided into two subscales: inattention ("IA", 9 items) and hyperactivity-impulsivity ("H/I", 9 items).The clinician rates the frequency and severity of each symptom on a 4-point Likert-type scale, where 0 = Never or rarely, 1 = Sometimes, 2 = Often, and 3 = Very often. The sum of the ratings of all 18 items yields the raw Total score (range: 0-54; the higher the Total score, the more severe the ADHD symptoms). Post-baseline raw Total scores are converted to a change from baseline Total score. A lower change from baseline ADHD-RS-IV-P Total Score (<0) represents a better outcome.

Baseline and Week 6

Sekundární výstupní opatření

Měření výsledku
Popis opatření
Časové okno
Change from Baseline in the Clinical Global Impression of Severity (CGI-S) Score at End of Study (Week 6)
Časové okno: Baseline and Week 6

The Clinical Global Impression of Severity (CGI-S) is a single item clinician-rated assessment of the severity of subject's condition (ADHD symptoms) in relation to the clinician's total experience with patients with ADHD. The CGI-S is evaluated on a 7-point scale with 1 = Normal, not at all ill, asymptomatic, 2 = Borderline Ill, 3 = Mildly Ill, 4 = Moderately Ill, 5 = Markedly Ill, 6 = Severely Ill, and 7 = Among the most extremely ill patients (the higher the score, the more severe the overall ADHD symptoms). Post-baseline (raw) CGI-S scores are converted to a change from baseline score. A lower change from baseline CGI-S score (<0) represents a better outcome.

Baseline and Week 6
Clinical Global Impression of Change (CGI-C) Score at End of Study (Week 6)
Časové okno: Week 6

The Clinical Global Impression of Change (CGI-C) is a single item clinician-rated assessment of how much the subject's condition (ADHD) has improved, worsened or has not changed relative to his/her baseline state prior to the beginning of treatment. The CGI-C is rated on a 7-point scale from 1 to 7, where 1 = "very much improved", 2 = "much improved", 3 = "minimally improved", 4 = "no change", 5 = "minimally worse", 6 = "much worse", and 7 = "very much worse". A CGI-C score <4 represents a better outcome.

Week 6
Change from Baseline in Attention-Deficit/Hyperactivity Disorder Rating Scale, 4th Edition, Preschool Version (ADHD-RS-IV-P) Hyperactivity/Impulsivity Subscale Score at End of Study (Week 6)
Časové okno: Baseline and Week 6

The Attention-Deficit/Hyperactivity Disorder Rating Scale, 4th Edition, Preschool Version (ADHD-RS-IV-P) consists of 18 items that correspond directly to the DSM-IV-TR criteria for ADHD. The scale is subdivided into two subscales: inattention ("IA", 9 items) and hyperactivity-impulsivity ("H/I" 9 items).The clinician rates the frequency and severity of each symptom on a 4-point Likert-type scale, where 0 = Never or rarely, 1 = Sometimes, 2 = Often, and 3 = Very often. The sum of the nine H/I items yields the raw H/I subscale score (range: 0-27; the higher the H/I subscale score, the more severe the H/I symptoms). Post-baseline raw H/I subscale scores are converted to a change from baseline score. A lower change from baseline H/I subscale score (<0) represents a better outcome.

Baseline and Week 6
Change from Baseline in Attention-Deficit/Hyperactivity Disorder Rating Scale, 4th Edition, Preschool Version (ADHD-RS-IV-P) Inattention Subscale Score at End of Study (Week 6)
Časové okno: Baseline and Week 6

The Attention-Deficit/Hyperactivity Disorder Rating Scale, 4th Edition, Preschool Version (ADHD-RS-IV-P) consists of 18 items that correspond directly to the DSM-IV-TR criteria for ADHD. The scale is subdivided into two subscales: inattention ("IA", 9 items) and hyperactivity-impulsivity ("H/I" 9 items).The clinician rates the frequency and severity of each symptom on a 4-point Likert-type scale, where 0 = Never or rarely, 1 = Sometimes, 2 = Often, and 3 = Very often. The sum of the nine IA items yields the raw IA subscale score (range: 0-27; the higher the IA subscale score, the more severe the IA symptoms). Post-baseline raw IA subscale scores are converted to a change from baseline score. A lower change from baseline IA subscale score (<0) represents a better outcome.

Baseline and Week 6
Clinical Global Impression of Severity (CGI-S) Responder Rate (percentage of subjects with CGI-S score of 1 or 2) at End of Study (Week 6)
Časové okno: Baseline and Week 6

The Clinical Global Impression of Severity (CGI-S) is a single item clinician-rated assessment of the severity of subject's condition (ADHD symptoms) in relation to the clinician's total experience with patients with ADHD. The CGI-S is evaluated on a 7-point scale with 1 = Normal, not at all ill, asymptomatic, 2 = Borderline Ill, 3 = Mildly Ill, 4 = Moderately Ill, 5 = Markedly Ill, 6 = Severely Ill, and 7 = Among the most extremely ill patients. The responder rate (percent) is calculated by dividing "the number of 'responders' (m)" by "the number of subjects analyzed at the respective Visit/Week (n)" and multiplying the product by 100. Responder Rate values range from 0 to 100%. A percent >50% represents a greater number of "responders" versus "non-responders".

Baseline and Week 6
Clinical Global Impression of Change (CGI-C) Responder Rate (percentage of subjects with CGI-C score of 1 or 2) at End of Study (Week 6)
Časové okno: Week 6

The Clinical Global Impression of Change (CGI-C) is a single item clinician-rated assessment of how much the subject's condition (ADHD) has improved, worsened or has not changed relative to his/her baseline state prior to the beginning of treatment. The CGI-C is rated on a 7-point scale from 1 to 7, where 1 = "very much improved", 2 = "much improved", 3 = "minimally improved", 4 = "no change", 5 = "minimally worse", 6 = "much worse", and 7 = "very much worse". The responder rate (percent) is calculated by dividing "the number of 'responders' (m)" by "the number of subjects analyzed at the respective Visit/Week (n)" and multiplying the product by 100. Responder Rate values range from 0 to 100%. A percent >50% represents a greater number of "responders" versus "non-responders".

Week 6
Attention-Deficit/Hyperactivity Disorder Rating Scale, 4th Edition, Preschool Version (ADHD-RS-IV-P) Responder Rate (percentage of subjects with ≥ 50% Reduction in Change from Baseline) at End of Study (Week 6)
Časové okno: Baseline and Week 6

The Attention-Deficit/Hyperactivity Disorder Rating Scale, 4th Edition, Preschool Version (ADHD-RS-IV-P) consists of 18 items that correspond directly to the DSM-IV-TR criteria for ADHD. The scale is subdivided into two 9 item subscales: inattention and hyperactivity-impulsivity. The clinician rates the frequency and severity of each symptom on a 4-point Likert-type scale; 0 = Never or rarely, 1 = Sometimes, 2 = Often, and 3 = Very often. Sum of 18 ratings yields the Total score (range: 0-54; higher score represents severer symptoms). Percent reduction is calculated for the ADHD-RS-IV-P score: [("Post-baseline"-"Baseline")/"Baseline"] x 100; range: 0 to 100%; a "responder" is a subject with a 50% or greater reduction in change from baseline Total score. Responder rate (percent of responders) is calculated: ["number of 'responders' (m)"/ "number of subjects analyzed" (n)] X 100; range: 0 to 100%. A Responder Rate greater than 50%, represents more "responders" versus "nonresponders".

Baseline and Week 6

Spolupracovníci a vyšetřovatelé

Zde najdete lidi a organizace zapojené do této studie.

Vyšetřovatelé

  • Ředitel studie: Joseph Hull, PhD, Supernus Pharmaceuticals, Inc.

Termíny studijních záznamů

Tato data sledují průběh záznamů studie a předkládání souhrnných výsledků na ClinicalTrials.gov. Záznamy ze studií a hlášené výsledky jsou před zveřejněním na veřejné webové stránce přezkoumány Národní lékařskou knihovnou (NLM), aby se ujistily, že splňují specifické standardy kontroly kvality.

Hlavní termíny studia

Začátek studia (Aktuální)

19. března 2024

Primární dokončení (Odhadovaný)

1. ledna 2028

Dokončení studie (Odhadovaný)

1. ledna 2028

Termíny zápisu do studia

První předloženo

26. února 2021

První předloženo, které splnilo kritéria kontroly kvality

1. března 2021

První zveřejněno (Aktuální)

4. března 2021

Aktualizace studijních záznamů

Poslední zveřejněná aktualizace (Aktuální)

5. října 2026

Odeslaná poslední aktualizace, která splnila kritéria kontroly kvality

2. října 2026

Naposledy ověřeno

1. října 2026

Více informací

Termíny související s touto studií

Klíčová slova

Další identifikační čísla studie

  • 812P401

Informace o lécích a zařízeních, studijní dokumenty

Studuje lékový produkt regulovaný americkým FDA

Ano

Studuje produkt zařízení regulovaný americkým úřadem FDA

Ne

Tyto informace byly beze změn načteny přímo z webu clinicaltrials.gov. Máte-li jakékoli požadavky na změnu, odstranění nebo aktualizaci podrobností studie, kontaktujte prosím register@clinicaltrials.gov. Jakmile bude změna implementována na clinicaltrials.gov, bude automaticky aktualizována i na našem webu .

Předplatit